Goldman Sachs’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Goldman Sachs’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Buy	+7,182	New	+$208K	﹤0.01%	6064
2023 Q3	–	Sell	-11,730	Closed	-$274K	–	5694
2023 Q2	$274K	Hold	11,730	–	–	﹤0.01%	5056
2023 Q1	$273K	Sell	11,730 -9,719	-45%	-$243K	﹤0.01%	5163
2022 Q4	$540K	Buy	21,449 +9,719	+83%	+$261K	﹤0.01%	4825
2022 Q3	$310K	Sell	11,730 -38,354	-77%	-$1.18M	﹤0.01%	5284
2022 Q2	$1.45M	Buy	50,084 +38,354	+327%	+$1.14M	﹤0.01%	4325
2022 Q1	$404K	Hold	11,730	–	–	﹤0.01%	5470
2021 Q4	$514K	Buy	+11,730	New	+$555K	﹤0.01%	5364

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Goldman Sachs's IDNA Position: Q1 2026 in Review

Goldman Sachs opened a new position in iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2026: 7,182 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #6064 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in IDNA as recently as Q2 2023.

Goldman Sachs first reported a position in IDNA in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.45M in Q2 2022. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Goldman Sachs held 7,182 shares of iShares Genomics Immunology and Healthcare ETF worth $209K as of Q1 2026.
iShares Genomics Immunology and Healthcare ETF was a new Goldman Sachs position in Q1 2026.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6064 holding.
Goldman Sachs first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and has held it in 8 quarters since.
Goldman Sachs's iShares Genomics Immunology and Healthcare ETF position peaked at $1.45M in Q2 2022.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.